Abstract
A convenient four-step approach to the synthesis of (S)-4-alkyl-2-(pyrrolidin-2-yl)oxazoles starting from l-Boc-proline inspired by naturally occurring oxazole-containing peptidomimetics is described. The key step is the cyclization of 1-Boc-N-(1-oxoalkan-2-yl)pyrrolidine-2-carboxamides – aldehyde intermediates which demonstrate low to moderate stability – under Appel reaction conditions. This method furnishes the target compounds with more than 98% ee and in a 17–51% overall yield and has been used at up to a 45-g scale.
Introduction
Since their isolation from marine products in the late 1980s, oxazole-containing peptidomimetics have been studied extensively by synthetic organic and medicinal chemists [1], [2], [3], [4], [5]. It is believed that many of these natural products are derived from enzymatic post-translational modifications of peptide-based precursors containing serine or threonine moieties [2]. It is not surprising, therefore, that 2,4-disubstituted oxazoles of general formula 1 derived from α-amino acids have attracted much attention as promising building blocks for drug discovery [6], [7], [8], [9], [10], [11], [12], [13] or total synthesis of natural products including plantazolicins [14], [15], telomestatin [16], ulapualides [17], [18] and diazonamide A [19], [20] and as ligands for enantioselective catalysis [21], [22]. In most cases, a ‘biomimetic’ approach to the synthesis of 1 has been used, including the formation of oxazoline 2 and its subsequent aromatization (Scheme 1) [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23]. However, this method is effective only when the substituent R1 in the oxazole ring formed is an electron-withdrawing group (e.g. R1=CO2Me). Even for R1=Ph, the aromatization step requires harsh conditions (NiO2, 150°C, μW) [13]. Recently, an alternative approach has been reported for the preparation of the compounds 1 with primary amino group (R3=H), which is based on oxidation of phthaloyl derivatives of the type 3 (R1=H, Ph, Bn; R2=i-Pr; R3/PG=phthaloyl) with the Dess-Martin reagent, followed by cyclodehydration and deprotection [6]. Apart from the limited scope, the method offers a moderate yield of the key step (34–50%) and can be used only at a milligram scale. Moreover, partial racemization occurs upon removal of the phthalimide protective group.

Biomimetic approach to oxazole building blocks.
In this work, we have taken inspiration from the ‘biocore’ concept described by Kombarov and co-workers [24]. This concept refers to a combination of (hetero)aliphatic and hydrophilic aromatic rings providing privileged structures for drug discovery (Figure 1). Analysis of the literature data published on ‘biocores’ obtained by a combination of oxazole and common heteroaliphatic amines (pyrrolidine/piperidine) shows that 2-(2-pyrrolidinyl)oxazoles 4 are most often encountered in papers and patents [25]. As in the case of the general structure 1, however, nearly all known compounds 4 are substituted with R1=aryl or CO2R, or are derived from them [7], [8], [9], [10], [11], [12], [21], [22], [23].

‘Biocore’ concept and its implementation into the target compounds 4.
Here, we describe the multigram synthesis of oxazole-substituted pyrrolidines 4 with aliphatic substituents at C-4 position (R1=H, alkyl; R2=H) starting from enantiopure (S)-N-Boc-proline (5 in Figure 1) [26]. Instant JChem was used for the prediction of the physico-chemical properties of the compounds. Conformational restriction provided by the saturated heteroaliphatic ring of 4 and an improved hydrophilicity are valuable features in lead-oriented synthesis in medicinal chemistry [27], [28].
Results and discussion
Our strategy for the preparation of the secondary amines 4a–e was related to the ‘biomimetic’ approaches shown in Scheme 1. Initially, the synthesis followed the literature analogs and involved dipeptides 6, which were prepared from 5 in an 85–95% yield using the mixed anhydride activation method (Scheme 2) [29]. However, reduction of 6a–e with NaBH4 was accompanied by a problematic isolation of the target products 7a–e, which was related to their high aqueous solubility and formation of stable boron complexes. Although compounds 7 were isolated in a 50–85% yield, the attempted scaling up of this procedure was not successful. Therefore, we switched to a one-step synthesis of 7 directly from 5 using coupling with β-amino alcohols 8 (either commercially available or prepared from the corresponding α-amino acids). Products 7a–f were obtained with overall yields of 60–86%. The procedure did not require chromatographic purification and was amenable to a multigram scale-up.

Synthesis of the compounds 4a–e·2HCl.
The next step, oxidation of 7 to aldehydes 9, was performed first with the Dess-Martin reagent, by analogy with the literature examples [6], [29] and our previous in-house experience. It was found that in the case of 7a, the yield of the product 9a varied significantly in different experiments [35–70% by 1H nuclear magnetic resonance (NMR)]. Moreover, the product 9a showed limited storage stability. A detailed investigation revealed that the Swern reaction [dimethyl sulfoxide (DMSO), (COCl)2, Et3N, −60°C, 1 h] gives more reproducible results, and the crude products 9a–d were obtained in a 55–85% yield (by 1H NMR). In the case of 7e (R1=H), the use of the Dess-Martin reagent appeared to be more fruitful than the Swern oxidation (35% vs. 5% yield of 9e by 1H NMR). Unfortunately, the product 9f (R1=Ph) could not be obtained at all using either method.
It was shown that the storage stability of products 9a–e is strongly affected by the steric volume of the substituent R1. In particular, the product 9a has limited stability in CH2Cl2 solution (ca. 1 h) and as a neat product at −24°C (ca. 8 h). On the contrary, compounds 9b–d with relatively bulky alkyl substituents are relatively stable in both cases (at least for 24 h). The product 7e is rather unstable either in CH2Cl2 solution or as a neat compound at −24°C (less than 1 h). Other factors influencing the stability of 9a–e include temperature which should be kept below 20°C during all manipulations with 9 including the evaporation of the solvent. It can be suggested that the stability of the products 9a–f is also related to their reactivity toward self-condensation, which is diminished upon an increase in the size of the alkyl substituent R1. In the case of R1=Ph, this side reaction becomes especially fast, presumably due to a concomitant increase in the acidity of α-CH adjacent to the aldehyde moiety. It was apparent that the use of acidic or basic reagents should be avoided during the synthesis of 9e, which might improve the yield of this product. For this reason, we have synthesized amide 7g (60% yield) and subjected it to oxidative cleavage with NaIO4. Using this procedure, the product 9e was obtained in a 45% yield.
Taking into account the low stability of aldehydes 9, the crude products 9 were used immediately in the next step, which is the dehydrative oxazole ring formation. The Appel reaction was used for this reason, by analogy with the literature results published previously [6], [29]. It was found that the use of the CBr4-PPh3 system gave a low yield of the target products 11 (less than 20% by 1H NMR), whereas with C2Cl6-PPh3, the oxazoles 11a–e were obtained in a 50–90% yield.
The structure of compound 11a was confirmed by X-ray single crystal analysis (CCDC-1570445 [30], Figure 2). It should be noted that only one enantiomer of 11a was observed in the crystal structure.

Molecular structure of compound 11a.
In the final step of the synthesis, deprotection of compounds 11a–e was performed by treatment with HCl. It was found that using a solution of HCl in Et2O resulted in precipitation of 11·HCl, so that a complete conversion could not be achieved. Fortunately, the use of HCl in Et2O-MeOH furnished the target products 4a–e as dihydrochlorides in a 76–85% yield. It should be noted that the method can be used for the synthesis of up to 45 g of the products 4·2HCl in a single run.
To analyze the optical purity of the products, compound 4a·2HCl was derivatized with the Mosher’s reagent, which gave a single diastereomer according to 1H NMR and 19F NMR analyses. In addition, the enantiomer of compound 11c was synthesized from D-N-Boc-proline and used as a control for chiral stationary phase high-performance liquid chromatography (HPLC). It was found that enantiopure product 11c showed no detectable peak of its enantiomer in the chromatogram [≥98% ee, (ChiralPack® IA column, hexanes – 2-propanol (95:5) as an eluent]. Under the same conditions, single peaks (≥98% ee) were also observed in the chromatograms of other products 11.
Conclusions
Synthesis of (S)-4-alkyl-2-(pyrrolidin-2-yl)oxazoles was performed starting from l-Boc-proline and using an approach inspired by biosynthesis of oxazole-containing peptidomimetics isolated from natural products. Optimization of the procedures was performed for each step, in order to make the method scalable. It was shown that the key intermediates, 1-Boc-N-(1-oxoalkan-2-yl)pyrrolidine-2-carboxamides (9), demonstrate low to moderate stability, which is increased with the increasing size of the alkyl group near the aldehyde moiety. Therefore, it is strongly recommended to submit them to the next step immediately after isolation.
The target products were obtained in only four steps from derivatives of natural α-amino acids in a 17–51% overall yield, with ≥98% ee and at up to a 45-g scale. The overall yield of the product is increased upon an increase in the lipophilicity of the compound and hence follows the ‘LogP drift’ effect proposed by Churcher and co-workers (Figure 3) [27]. In our opinion, this effect might be related to isolation issues observed for more hydrophilic compounds.

Overall yields of products 4a–e·2HCl as a function of their lipophilicity.
In conclusion, (S)-4-alkyl-2-(pyrrolidin-2-yl)oxazoles can be considered as building blocks readily available to the chemical community. We believe that synthetic accessibility and favorable physico-chemical characteristics of these oxazole-derived ‘biocores’ make them valuable starting points for early drug discovery.
Experimental
Solvents were purified according to standard procedures [31]. Compounds 6a–e [29], 8b–d and 8f [32] were prepared using reported methods. All other starting materials were purchased from commercial sources. Analytical thin-layer chromatography (TLC) was performed using Polychrom SI F254 plates. Column chromatography was performed using Kieselgel Merck 60 (230–400 mesh) as the stationary phase. NMR spectra were recorded on a Bruker 170 Avance 500 spectrometer (500 MHz for 1H and 125 MHz for 13C). Signal assignments for compounds 4a–e·2HCl were made using 1H-1H correlation spectroscopy (COSY), heteronuclear single quantum coherence (HSQC) and heteronuclear multiple bond correlation (HMBC) experiments. Mass spectra were recorded on an Agilent 1100 LC/MSD SL instrument [atmospheric pressure electrospray ionization (APESI)]. The stability of aldehydes 9 in CH2Cl2 solution or as neat products at −24°C was studied by recording 1H NMR spectra for the aliquots hourly; the compound was assumed to be stable if the relative intensity of the aldehyde signal changed by no more than 10%.
General procedure for synthesis of amides 7a–g
Isobutyl chloroformate (41.2 g, 0.30 mol or methyl chloroformate) was added dropwise to a solution of l-Boc-proline (65.0 g, 0.30 mol) and N,N-diisopropylethylamine (DIPEA) (42.6 g, 0.33 mol) in anhydrous CH2Cl2 (1200 mL) at 0°C. After 1 h at room temperature, the mixture was cooled to −15°C and then amino alcohol 8 (0.33 mol) and DIPEA (42.6 g, 0.33 mol) were added in one portion. The mixture was slowly warmed to room temperature and stirred overnight. The volatiles were removed under reduced pressure, and the solid residue was triturated with Et2O (400 mL), filtered, washed with Et2O (200 mL) and then with H2O (100 mL). As the product is water soluble, it is necessary to use a minimal amount of H2O at this step. The product 7 was dried under reduced pressure.
tert-Butyl (S)-2-[((S)-1-hydroxypropan-2-yl)carbamoyl]-pyrrolidine-1-carboxylate (7a)
Yield 62.9 g (63%); white solid; mp 175–178°C; MS: m/z 295 (MNa+); 1H NMR (CDCl3): δ 6.82 (br s, 0.68H, NH) and 6.23 (br s, 0.32H, NH), 4.24 (br s, 1H), 4.02 (br s, 1H), 3.78–3.58 (m, 1H), 3.58–3.24 (m, 4H), 2.35–1.74 (m, 4H), 1.46 (s, 9H), 1.15 (d, J=6.4 Hz, 3H); 13C NMR (CDCl3): δ 172.1, 155.3, 80.3, 66.1, 60.8 and 59.9, 47.5, 46.8, 30.9, 28.1, 24.3 and 23.5, 16.7. Anal. Calcd for C13H24N2O4: C, 57.33; H, 8.88; N, 10.29. Found: C, 57.06; H, 8.77; N, 10.19.
tert-Butyl (S)-2-[((S)-1-hydroxy-3-methylbutan-2-yl)carbamoyl]pyrrolidine-1-carboxylate (7b)
Yield 96.7 g (86%); white solid; mp 112–115°C; MS: m/z 301 (MH+); 1H NMR (CDCl3): δ 6.93 (br s, 0.77H) and 6.28 (br s, 0.33H), 4.30 (br s, 1H), 3.75–3.65 (m, 2H), 3.59 (br s, 1H), 3.52–3.27 (m, 2H), 3.24–2.43 (m, 1H), 2.40–1.65 (m, 5H), 1.46 (s, 9H), 0.93 (d, J=6.8 Hz, 3H), 0.90 (d, J=6.8 Hz, 3H); 13C NMR (CDCl3): δ 172.2, 155.4 and 154.3, 80.3, 63.3, 61.0 and 60.0, 56.8, 46.8, 30.8, 28.6 and 28.1, 24.3 and 23.5, 19.4, 18.1. Anal. Calcd for C15H28N2O4: C, 59.97; H, 9.40; N, 9.33. Found: C, 59.80; H, 9.61; N, 9.10.
tert-Butyl (S)-2-[((S)-1-hydroxy-4-methylpentan-2-yl)carbamoyl]pyrrolidine-1-carboxylate (7c)
Yield 76.2 g (82%); white solid; mp 99–102°C; MS: m/z 337(MNa+), 315 (MH+); 1H NMR (CDCl3): δ 6.75 (br s, 0.66H) and 6.17 (br s, 0.34H), 4.23 (br s, 1H), 3.97 (br s, 1H), 3.62 (br s, 1H), 3.56–2.89 (m, 4H), 2.33–1.73 (m, 4H), 1.65–1.52 (m, 1H), 1.44 (s, 9H), 1.38–1.21 (m, 2H), 0.89 (d, J=6.6 Hz, 3H), 0.87 (d, J=6.6 Hz, 3H); 13C NMR (CDCl3): δ 172.1, 155.3 and 154.21, 80.3, 65.5, 60.8 and 60.0, 49.9, 46.8, 39.8, 30.8, 28.1, 24.6 and 23.5, 22.9, 21.8. Anal. Calcd for C16H30N2O4: C, 61.12; H, 9.62; N, 8.91. Found: C, 61.07; H, 9.49; N, 9.01.
tert-Butyl (2S)-2-[(1-hydroxy-3,3-dimethylbutan-2-yl)carbamoyl]pyrrolidine-1-carboxylate (7d)
Yield 90.4 g (84%); white solid; mp 122–125°C; MS: m/z 337 (MNa+), 315 (MH+); 1H NMR (CDCl3): δ 6.99 (br s, 0.85H) and 6.27 (br s, 0.15H), 4.33 (br s, 1H), 3.91–3.68 (m, 2H), 3.60–3.23 (m, 3H), 2.84 (s, 0.77H) and 2.53 (s, 0.23H), 2.43–1.81 (m, 4H), 1.47 (s, 9H), 0.92 (s, 9H); 13C NMR (CDCl3): δ 172.3, 155.5, 80.4, 62.7, 61.1, 60.0 and 59.6, 46.9, 33.1, 30.7, 28.1, 26.6, 24.4. Anal. Calcd for C16H30N2O4: C, 61.12; H, 9.62; N, 8.91. Found: C, 60.74; H, 9.92; N, 8.95.
tert-Butyl (S)-2-[(2-hydroxyethyl)carbamoyl]pyrrolidine-1-carboxylate (7e)
Yield 63.0 g (65%); white solid; mp 157–159°C (lit. [33] mp 157–158°C). All other spectral and physical data are in accordance with the literature.
tert-Butyl (S)-2-[((S)-2-hydroxy-1-phenylethyl)carbamoyl]pyrrolidine-1-carboxylate (7f)
Yield 85.2 g (78%); white solid; mp 121–124°C; MS: m/z 334 (MH+); 1H NMR (CDCl3): δ 7.54 (br s, 0.45H) and 6.74 (br s, 0.55H), 7.48–6.97 (m, 5H), 5.05 (br s, 1H), 4.45–4.12 (m, 1H), 4.00–3.66 (m, 2H), 3.59–3.06 (m, 2H), 2.95 (br s, 1H), 2.50–1.65 (m, 4H), 1.45 (s, 9H); 13C NMR (CDCl3): δ 172.4, 156.0 and 154.8, 139.1, 128.7, 127.6, 126.7 and 126.6, 80.7 and 80.6, 66.4 and 66.1, 61.2 and 60.2, 55.7, 47.1, 30.9, 28.3, 24.6 and 23.8. Anal. Calcd for C18H26N2O4: C, 64.65; H, 7.84; N, 8.38. Found: C, 64.50; H, 7.69; N, 8.37.
tert-Butyl (2S)-2-[(2,3-dihydroxypropyl)carbamoyl]pyrrolidine-1-carboxylate (7g)
The product was obtained according to the general procedure except for the work-up step. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography using CHCl3/MeOH (14:1) as an eluent to give the pure compound as a clear viscous oil which solidified overnight: yield 25.6 g (60%); white crystals; mp 95–97°C; Rf 0.38 [CHCl3/MeOH (14:1)]; 1H NMR (CDCl3): δ 7.16 (br s, 0.6H) and 6.97 (s, 0.4H), 4.26–4.10 (m, 1H), 4.08–3.78 (m, 2H), 3.78–3.66 (m, 1H), 3.56–3.19 (m, 6H), 2.31–1.60 (m, 4H), 1.40 (s, 9H); 13C NMR (CDCl3): δ 174.5 and 173.9, 155.5 and 154.7, 80.7, 70.8, 63.6, 61.1 and 60.3, 47.2, 42.0, 31.2, 29.3 and 28.3, 24.5 and 23.7. Anal. Calcd for C13H24N2O5: C, 54.15; H, 8.39; N, 9.72. Found: C, 54.49; H, 8.62; N, 9.34. MS (CI): 289 (MH+).
General procedure for synthesis of aldehydes 9a–e
Method A
A suspension of alcohol 7 (0.12 mol) in CH2Cl2 (100 mL) was added in small portions to a solution of the Dess-Martin reagent (60.6 g, 0.14 mol) and t-BuOH (9.70 g, 0.13 mol) in CH2Cl2 (800 mL) at 0°C. Then the mixture was allowed to warm to room temperature, and after the reaction was complete, as monitored by TLC, about 1 h, the excess of the Dess-Martin reagent was neutralized with a solution of Na2S2O3 (20 g) in saturated aqueous NaHCO3 (400 mL) with stirring. After an additional 10 min of stirring, the mixture was transferred into a separatory funnel. The organic phase was separated, washed with brine (200 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product 9a–e which was immediately used in the next step without purification. The temperature should be kept below 20°C during all manipulations with the product, including the evaporation of the solvent.
Method B
A solution of DMSO (28.7 g, 0.37 mol) in CH2Cl2 (80 mL) was added dropwise to a solution of oxalyl chloride (22.3 g, 0.18 mol) in CH2Cl2 (1100 mL) at –60°C. The mixture was stirred for 20 min at the same temperature and then treated with a suspension of alcohol 7 (0.15 mol) in CH2Cl2 (100 mL) at –60°C. The solution was stirred for an additional 30 min at –60°C, then Et3N (79.9 g, 0.73 mol) was added and the mixture was allowed to warm to 15°C. Water (250 mL) was added, the mixture was stirred for 5 min and the organic phase was separated. The aqueous phase was washed with CH2Cl2 (150 mL). The combined organic extracts were dried over Na2SO4 and concentrated under reduced pressure to give the crude compound which was immediately used in the next step without purification. The temperature should be kept below 20°C during all manipulations with the product, including the evaporation of the solvent. For comparative analysis of the methods A and B, see the main text.
tert-Butyl (S)-2-[(2-oxoethyl)carbamoyl]pyrrolidine-1-carboxylate (9e) (alternative procedure)
NaIO4 (37.2 g, 0.17 mol) was added in portions to a stirred solution of diol 7g (25.0 g, 0.087 mol) in tetrahydrofuran (THF) (250 mL) and H2O (250 mL) at 5–10°C. After stirring at 20°C for 1 h, the mixture was extracted with Et2O (4×150 mL) and the combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The temperature should be kept below 20°C during all manipulations with the product, including the evaporation of the solvent. The crude product 9e was immediately used in the next step without purification.
General procedure for synthesis of oxazoles 11a–e
Ph3P (115.5 g, 0.44 mol) was added to a stirred solution of C2Cl6 (104.3 g, 0.44 mol) in dry MeCN (1200 mL). The mixture was cooled to 0°C and treated with Et3N (89.0 g, 0.88 mol). The mixture was kept at this temperature for 10 min, and a solution of aldehyde 9 (0.15 mol) in dry MeCN (100 mL) was added in small portions, with the temperature kept between 0 and 10°C. The resulting mixture was stirred at room temperature for 14 h. The solvent was evaporated and the residue was triturated with Et2O (400 mL). The precipitate was filtered, washed with saturated aqueous NaHCO3 (to pH~8) and then with Et2O (2×200 mL). The organic layer was separated, washed with brine (300 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography to give 11.
tert-Butyl (S)-2-(4-methyloxazol-2-yl) pyrrolidine-1-carboxylate (11a)
Yield 22.1 g (60% for two steps); white solid; mp 55–57°C; Rf 0.45 [hexanes/EtOAc (1:1)];
tert-Butyl (S)-2-(4-isopropyloxazol-2-yl) pyrrolidine-1-carboxylate (11b)
Yield 61.4 g (70% for two steps); yellowish oil; Rf 0.41 [hexanes/EtOAc (4:1)];
tert-Butyl (S)-2-(4-isobutyloxazol-2-yl)pyrrolidine-1-carboxylate (11c)
Yield 44.8 g (63% for two steps); yellowish oil; Rf 0.35 [hexanes/EtOAc (4:1)];
tert-Butyl (S)-2-(4-(tert-butyl)oxazol-2-yl)pyrrolidine-1-carboxylate (11d)
Yield 60.7 g (72% for two steps); beige solid; mp 66–67°C; Rf 0.43 [hexanes/EtOAc (4:1)];
tert-Butyl (S)-2-(oxazol-2-yl)pyrrolidine-1-carboxylate (11e)
Yield 25.0 g (35% for two steps); yellowish oil; Rf 0.52 [hexanes/EtOAc (1:1)];
General procedure for synthesis of oxazoles 4a–e·2HCl
A saturated solution of HCl in Et2O (ca. 24% w/w, 100 mL) was pre-cooled to 5°C and added in portions to a solution of Boc derivative 11 (0.15 mol) in dry MeOH (200 mL) at room temperature. The mixture was stirred vigorously at room temperature overnight, then concentrated (caution: violent gas emission) under reduced pressure and the residue was triturated with Et2O (200 mL). The precipitate was filtered and washed thoroughly with MeCN (80 mL) and dried under reduced pressure to give the title product 4·2HCl.
(S)-4-Methyl-2-(pyrrolidin-2-yl)oxazole dihydrochloride (4a· 2HCl)
Yield 26.5 g (77%); white solid; mp 126–128°C;
(S)-4-Isopropyl-2-(pyrrolidin-2-yl)oxazole dihydrochloride (4b· 2HCl)
Yield 43.1 g (80%); white solid; mp 134–136°C;
(S)-4-Isobutyl-2-(pyrrolidin-2-yl)oxazole dihydrochloride (4c· 2HCl)
Yield 45.0 g (82%); white solid; mp 108–111°C;
(S)-4-(tert-Butyl)-2-(pyrrolidin-2-yl)oxazole dihydrochloride (4d·2HCl)
Yield 38.2 g (85%); white solid; mp 141–142°C (dec.);
(S)-2-(Pyrrolidin-2-yl)oxazole dihydrochloride (4e·2HCl)
Yield 16.9 g (76%); beige solid; mp 167–169°C (dec.);
Acknowledgments
This work was supported by Life Chemicals Inc., Enamine Ltd. and Ukrainian Government Funding (state registry no. 0114U003956). The authors thank Prof. Andrey A. Tolmachev for his encouragement and support, Mr. Andriy Kozitskiy for 2D NMR measurements and Dr. Valeriya Makhankova for her help with manuscript preparation.
References
[1] Roy, R. S.; Gehring, A. M.; Milne, J. C.; Belshaw, P. J.; Walsh, C. T. Thiazole and oxazole peptides: biosynthesis and molecular machinery. Nat. Prod. Rep.1999, 16, 249–263.10.1039/a806930aSearch in Google Scholar PubMed
[2] Yeh, V. S. C. Recent advances in the total synthesis of oxazolecontaining natural products. Tetrahedron2004, 60, 11995–12042.10.1016/j.tet.2004.10.001Search in Google Scholar
[3] Melby, J. O.; Nard, N. J.; Mitchell, D. A. Thiazole/oxazole-modified microcins: complex natural products from ribosomal templates. Curr. Opin. Chem. Biol.2011, 15, 369–378.10.1016/j.cbpa.2011.02.027Search in Google Scholar PubMed PubMed Central
[4] Davyt, D.; Serra, G. Thiazole and oxazole alkaloids: isolation and synthesis. Mar. Drugs2010, 8, 2755–2780.10.3390/md8112755Search in Google Scholar PubMed PubMed Central
[5] Tilvi, S.; Singh, K. S. Synthesis of oxazole, oxazoline and isoxazoline derived marine natural products: a review. Curr. Org. Chem.2016, 20, 898–929.10.2174/1385272819666150804000046Search in Google Scholar
[6] Wales, S. M.; Hammer, K. A.; Somphol, K.; Kemker, I.; Schröder, D. C.; Tague, A. J.; Brkic, Z.; King, A. M.; Lyras, D.; Riley, T. V.; et al. Synthesis and antimicrobial activity of binaphthyl-based, functionalized oxazole and thiazole peptidomimetics. Org. Biomol. Chem.2015, 13, 10813–10824.10.1039/C5OB01638JSearch in Google Scholar
[7] Murru, S.; Nefzi, A. Combinatorial synthesis of oxazol-thiazole bis-heterocyclic compounds. ACS Comb. Sci.2014, 16, 39–45.10.1021/co400133aSearch in Google Scholar PubMed
[8] Blankson, G. A.; Pilch, D. S.; Liu, A. A.; Liu, L. F.; Rice, J. E.; Lavoie, E. J. Macrocyclic biphenyl tetraoxazoles: synthesis, evaluation as G-quadruplex stabilizers and cytotoxic activity. Bioorg. Med. Chem.2013, 21, 4511–4520.10.1016/j.bmc.2013.05.033Search in Google Scholar PubMed PubMed Central
[9] Murru, S.; Dooley, C. T.; Nefzi, A. Parallel synthesis of bis-oxazole peptidomimetics. Tetrahedron Lett.2013, 54, 7062–7064.10.1016/j.tetlet.2013.10.078Search in Google Scholar
[10] Shibata, K.; Yoshida, M.; Takahashi, T.; Takagi, M.; Shin-Ya, K.; Doi, T. Synthesis of heptaoxazole macrocyclic analogues of telomestatin and evaluation of their telomerase inhibitory activities. Bull. Chem. Soc. Jpn.2013, 86, 1453–1465.10.1246/bcsj.20130198Search in Google Scholar
[11] Doi, T.; Shibata, K.; Yoshida, M.; Takagi, M.; Tera, M.; Nagasawa, K.; Shin-Ya, K.; Takahashi, T. (S)-Stereoisomer of telomestatin as a potent G-quadruplex binder and telomerase inhibitor. Org. Biomol. Chem.2011, 9, 387–393.10.1039/C0OB00513DSearch in Google Scholar
[12] Oost, T.; Backfisch, G.; Bhowmik, S.; Van Gaalen, M. M.; Geneste, H.; Hornberger, W.; Lubisch, W.; Netz, A.; Unger, L.; Wernet, W. Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties. Bioorg. Med. Chem. Lett.2011, 21, 3828–3831.10.1016/j.bmcl.2011.03.012Search in Google Scholar PubMed
[13] Nordhoff, S.; Bulat, S.; Cerezo-Gálvez, S.; Hill, O.; Hoffmann-Enger, B.; López-Canet, M.; Rosenbaum, C.; Rummey, C.; Thiemann, M.; Matassa, V. G.; et al. The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements. Bioorg. Med. Chem. Lett.2009, 19, 6340–6345.10.1016/j.bmcl.2009.09.078Search in Google Scholar PubMed
[14] Fenner, S.; Wilson, Z. E.; Ley, S. V. The total synthesis of the bioactive natural product plantazolicin A and its biosynthetic precursor plantazolicin B. Chem. Eur. J.2016, 22, 15902–15912.10.1002/chem.201603157Search in Google Scholar PubMed
[15] Wada, H.; Williams, H. E. L.; Moody, C. J. Total synthesis of the posttranslationally modified polyazole peptide antibiotic plantazolicin A. Angew. Chem. Int. Ed.2015, 54, 15147–15151.10.1002/anie.201507062Search in Google Scholar PubMed
[16] Linder, J.; Garner, T. P.; Williams, H. E. L.; Searle, M. S.; Moody, C. J. Telomestatin: formal total synthesis and cation-mediated interaction of its seco-derivatives with G-quadruplexes. J. Am. Chem. Soc.2011, 133, 1044–1051.10.1021/ja109158kSearch in Google Scholar PubMed
[17] Pattenden, G.; Ashweek, N. J.; Baker-Glenn, C. A. G.; Kempson, J.; Walker, G. M.; Yee, J. G. K. Total synthesis of (−)-ulapualide A, a novel tris-oxazole macrolide from marine nudibranchs, based on some biosynthesis speculation. Org. Biomol. Chem.2008, 6, 1478–1497.10.1039/b801036fSearch in Google Scholar PubMed
[18] Pattenden, G.; Ashweek, N. J.; Baker-Glenn, C. A. G.; Walker, G. M.; Yee, J. G. K. Total synthesis of (−)-ulapualide A: the danger of overdependence on NMR spectroscopy in assignment of stereochemistry. Angew. Chem. Int. Ed.2007, 46, 4359–4363.10.1002/anie.200700459Search in Google Scholar PubMed
[19] David, N.; Pasceri, R.; Kitson, R. R. A.; Pradal, A.; Moody, C. J. Formal total synthesis of diazonamide A by indole oxidative rearrangement. Chem. Eur. J.2016, 22, 10867–10876.10.1002/chem.201601605Search in Google Scholar PubMed
[20] Nicolaou, K. C.; Chen, D. Y.-K.; Huang, X.; Ling, T.; Bella, M.; Snyder, S. A. Chemistry and biology of diazonamide A: first total synthesis and confirmation of the true structure. J. Am. Chem. Soc.2004, 126, 12888–12896.10.1021/ja040092iSearch in Google Scholar PubMed
[21] Wiedenhoeft, D.; Benoit, A. R.; Wu, Y.; Porter, J. D.; Meyle, E.; Yeung, T. H. W.; Huff, R.; Lindeman, S. V.; Dockendorff, C. Multifunctional heterocyclic scaffolds for hybrid Lewis acid/Lewis base catalysis of carbon-carbon bond formation. Tetrahedron2016, 72, 3905–3916.10.1016/j.tet.2016.05.014Search in Google Scholar
[22] Wiedenhoeft, D.; Benoit, A. R.; Porter, J. D.; Wu, Y.; Virdi, R. S.; Shanaa, A.; Dockendorff, C. Design and synthesis of oxazoline-based scaffolds for hybrid Lewis acid/Lewis base catalysis of carbon-carbon bond formation. Synthesis2016, 48, 2413–2422.10.1055/s-0035-1560436Search in Google Scholar
[23] Loos, P.; Ronco, C.; Riedrich, M.; Arndt, H.-D. Unified azoline and azole syntheses by optimized aza-Wittig chemistry. Eur. J. Org. Chem.2013, 2013, 3290–3315.10.1002/ejoc.201300160Search in Google Scholar
[24] Kombarov, R.; Altieri, A.; Genis, D.; Kirpichenok, M.; Kochubey, V.; Rakitina, N.; Titarenko, Z. BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery. Mol. Divers.2010, 14, 193–200.10.1007/s11030-009-9157-5Search in Google Scholar PubMed
[25] Reaxys® Database, www.reaxys.com, accessed on 20 June 2017.Search in Google Scholar
[26] Instant JChem version 17.2.13.0, 2017, ChemAxon (http://www.chemaxon.com).Search in Google Scholar
[27] Nadin, A.; Hattotuwagama, C.; Churcher, I. Lead-oriented synthesis: a new opportunity for synthetic chemistry. Angew. Chem. Int. Ed.2012, 51, 1114–1122.10.1002/anie.201105840Search in Google Scholar PubMed
[28] Goldberg, F. W.; Kettle, J. G.; Kogej, T.; Perry, M. W.; Tomkinson, N. P. Designing novel building blocks is an overlooked strategy to improve compound quality. Drug Discov. Today2015, 20, 11–17.10.1016/j.drudis.2014.09.023Search in Google Scholar PubMed
[29] Wang, B.; Chen, G.-H.; Liu, L.-Y.; Chang, W.-X.; Li, J. A novel proline-valinol thioamide small organic molecule for a highly enantioselective direct aldol reaction. Adv. Synth. Catal.2009, 351, 2441–2448.10.1002/adsc.200900427Search in Google Scholar
[30] CCDC-1570445 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre viawww.ccdc.cam.ac.uk/data_request/cif.Search in Google Scholar
[31] Armarego, W. L. F.; Chai, C. L. L. Purification of Laboratory Chemicals; Elsevier: Oxford, 2003.10.1016/B978-075067571-0/50008-9Search in Google Scholar
[32] Yi, H.; Louis, S. H. Synthesis of optically active imidazolines, azapenams, dioxocyclams, and bis-dioxocyclams. J. Org. Chem.1997, 62, 3586–3591.10.1021/jo962343eSearch in Google Scholar
[33] Pedrosa, R.; Andres, J. M.; Gamarra, A.; Manzano, R.; Perez-Lopez, C. Novel sulfonylpolystyrene-supported prolinamides as catalysts for enantioselective aldol reaction in water. Tetrahedron2013, 69, 10811–10819.10.1016/j.tet.2013.10.093Search in Google Scholar
©2018 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review
- Research progress in quinazoline derivatives as multi-target tyrosine kinase inhibitors
- Research Articles
- A bio-inspired approach to proline-derived 2,4-disubstituted oxazoles
- Solvent-free preparation of 3-aryl-2-[(aryl)(arylamino)]methyl-4H-furo[3,2-c]chromen-4-one derivatives using ZnO-ZnAl2O4 nanocomposite as a heterogeneous catalyst
- Synthesis of 4-arylethyl-6-arylpyrimidine-2-thiols through aza-Michael addition/nucleophilic addition/aromatization tandem reactions
- 3-Carboxy-1-sulfopyridin-1-ium chloride ([CPySO3H]+Cl−): an efficient catalyst for one-pot synthesis of hexahydroquinoline-3-carboxamides
- Synthesis of new 3H-chromeno[2,3-d]pyrimidine-4,6(5H,7H)-diones via the tandem intramolecular Pinner/Dimroth rearrangement
- A new synthesis of pyrrolo[3,2-d]pyrimidine derivatives by a one-pot, three-component reaction in the presence of L-proline as an organocatalyst
- Diversity-oriented synthesis of amide derivatives of tricyclic thieno[2,3-d]pyrimidin-4(3H)-ones and evaluation of their influence on melanin synthesis in murine B16 cells
- Synthesis, crystal structure, molecular docking studies and bio-evaluation of some N4-benzyl-substituted isatin- 3-thiosemicarbazones as urease and glycation inhibitors
- Ultrasound-assisted synthesis and antimicrobial activity of tetrazole-based pyrazole and pyrimidine derivatives
Articles in the same Issue
- Frontmatter
- Review
- Research progress in quinazoline derivatives as multi-target tyrosine kinase inhibitors
- Research Articles
- A bio-inspired approach to proline-derived 2,4-disubstituted oxazoles
- Solvent-free preparation of 3-aryl-2-[(aryl)(arylamino)]methyl-4H-furo[3,2-c]chromen-4-one derivatives using ZnO-ZnAl2O4 nanocomposite as a heterogeneous catalyst
- Synthesis of 4-arylethyl-6-arylpyrimidine-2-thiols through aza-Michael addition/nucleophilic addition/aromatization tandem reactions
- 3-Carboxy-1-sulfopyridin-1-ium chloride ([CPySO3H]+Cl−): an efficient catalyst for one-pot synthesis of hexahydroquinoline-3-carboxamides
- Synthesis of new 3H-chromeno[2,3-d]pyrimidine-4,6(5H,7H)-diones via the tandem intramolecular Pinner/Dimroth rearrangement
- A new synthesis of pyrrolo[3,2-d]pyrimidine derivatives by a one-pot, three-component reaction in the presence of L-proline as an organocatalyst
- Diversity-oriented synthesis of amide derivatives of tricyclic thieno[2,3-d]pyrimidin-4(3H)-ones and evaluation of their influence on melanin synthesis in murine B16 cells
- Synthesis, crystal structure, molecular docking studies and bio-evaluation of some N4-benzyl-substituted isatin- 3-thiosemicarbazones as urease and glycation inhibitors
- Ultrasound-assisted synthesis and antimicrobial activity of tetrazole-based pyrazole and pyrimidine derivatives